Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01816776
Other study ID # Respicardia CR-1005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2013
Est. completion date November 7, 2017

Study information

Verified date May 2018
Source Respicardia, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remedē® systems.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date November 7, 2017
Est. primary completion date September 10, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. At least 18 years of age

2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of scheduled implant:

- Apnea/Hypopnea Index (AHI) greater than or equal to 20;

- Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central apnea events;

- Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI

3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no hospitalizations for illness, no breathing mask-based therapy, and on stable medications and therapies:

- Stable medications are defined as no changes during this period except for those within a pre-specified sliding scale medication regimen;

- If the subject has heart failure, the baseline testing (including PSG) should occur at least 6 months after initial diagnosis;

- If the subject has systolic heart failure, the baseline testing (including PSG) should occur after maximally titrating beta blockers, angiotensin converting enzyme inhibitors (ACE-I) and other medications indicated in the current guidelines (unless contraindicated or not considered medically necessary) and after receiving any indicated device therapy including devices for cardiac resynchronization therapy and/or primary prevention of sudden cardiac death;

- If subject has a hospitalization or physician visit requiring IV medication between the screening PSG and implant, the subject must be re-screened when stable

4. Expected to tolerate study procedures in the opinion of the investigator, in particular:

- Ability to lie down long enough to insert the remede system without shortness of breath and able to tolerate instrumentation for the Polysomnogram/Polygram testing;

- Expected to tolerate therapy titration and the sensation of therapy, and communicate therapy experience.

5. In the investigator's opinion, willing and able to comply with all study requirements

6. Signed the Institutional Review Board/Medical Ethics Committee approved informed consent (HIPAA authorization in the U.S.)

Exclusion Criteria:

1. Pacemaker dependent subjects without any physiologic escape rhythm

2. Suspected inability to place catheter for delivery of stimulation lead (e.g. previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.)

3. Evidence of phrenic nerve palsy

4. More than 2 previous open chest surgical procedures (e.g., CABG)

5. Etiology of central sleep apnea known to be caused primarily by pain medication

6. Documented history of psychosis or severe bipolar disorder

7. Cerebrovascular accident (CVA) within 12 months of baseline testing

8. History of idiopathic pulmonary hypertension, World Health Organization Class 1

9. Limited pulmonary function with either forced expiratory volume (FEV) 1/forced vital capacity (FVC) less than 65% of predicted value or FVC less than 60% of predicted value

10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes of quiet rest

11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6 months post therapy initiation visit

12. Active infection or sepsis within 30 days of enrollment

13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault equation

14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab normals at each site)

15. Hemoglobin less than 8 gm/dL

16. In subjects with heart failure, American College of Cardiology (ACC)/American Heart Association Heart (AHA) Stage D

17. Within the 3 months prior to baseline testing, any of the following: uncorrected severe valvular stenosis, valve replacement or repair (percutaneous or surgical), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, percutaneous coronary intervention (PCI), cardiac ablation, new cardiac resynchronization device or new pacemaker implant

18. New implantable cardioverter defibrillator or any implantable device generator change-out within 30 days prior to baseline testing or anticipated within the first 6 months of enrollment

19. Other anticipated surgery or invasive procedure expected to affect ability to perform testing at 6-month post-therapy initiation visit

20. Unstable angina

21. Allergy to or intolerant of contrast dye

22. Pregnancy or of child bearing potential without a negative pregnancy test within 10 days prior to remede system implant

23. Life expectancy or expected time to transplant or left ventricular assist device of less than 12 months

24. Currently enrolled or planning to enroll in another study that may conflict with protocol requirements or confound subject results in this trial

Study Design


Intervention

Device:
Treatment Group (transvenous stimulation of the phrenic nerve)
device implant, optimal medical therapy and device initiation 1 month post implant.
Control Group (Optimal Medical Therapy)
device implant, optimal medical therapy and delayed device initiation (7 months post device implant)

Locations

Country Name City State
Germany Bad Oeynhausen- Heart & Diabetes Center Bad Oeynhausen
Germany Charite Medical School, Campus Virchow-Klinikum Berlin
Germany Bernau-Herzzentruym Brandenburg Bernau
Germany Bielefeld-Klinikun Bielefeld
Germany Hamburg: Universitares Herzzentrum Hamburg
Germany Ambulantes Herzzentrum-Kassel Kassel
Poland Fourth Military Hospital Wroclaw
United States Johns Hopkins Bayview Medical Center Baltimore Maryland
United States University of Maryland, Baltimore Baltimore Maryland
United States Novant Medical Group, Inc. Presbyterian Sleep Health Charlotte Charlotte North Carolina
United States Cooper Health System Cherry Hill New Jersey
United States The Lindner Center for Research and Education at Christ Hospital Cincinnati Ohio
United States Ohio State University Columbus Ohio
United States Advocate Medical Group Downers Grove Illinois
United States Detroit Clinical Research Center Farmington Hills Michigan
United States Spectrum Health Grand Rapids Michigan
United States University of Florida - Jacksonville Jacksonville Florida
United States Mid America Heart Institute Kansas City Missouri
United States Lancaster General Hospital Lancaster Pennsylvania
United States Bryan Heart Lincoln Nebraska
United States Keck Hospital of USC Los Angeles California
United States Marshfield Clinic Marshfield Wisconsin
United States Stern Cardiovascular Memphis Tennessee
United States Edward Hospital-Advocate Medical Group Naperville Illinois
United States Hospital of University of Pennsylvania Philadelphia Pennsylvania
United States Virginia Commonwealth University Richmond Virginia
United States Washington University Saint Louis Missouri
United States United Heart and Vascular (Allina) Saint Paul Minnesota
United States Methodist Healthcare System San Antonio Texas
United States Forsyth Medical Center - Novant Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Respicardia, Inc.

Countries where clinical trial is conducted

United States,  Germany,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI) Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group. 6 months
Primary Freedom From Related Serious Adverse Events Within 12 Months Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit. 12 months
Secondary Central Apnea Index (CAI) Change From Baseline at 6 Months Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep. 6 months
Secondary Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. 6 months
Secondary Arousal Index (ArI) Change From Baseline at 6 Months Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted. 6 months
Secondary Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality. 6 months
Secondary The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months The proportion of subjects with a "moderate" or "marked" improvement in the Patient Global Assessment from baseline to the 6 month visit 6 months
Secondary Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops =4%. 6 months
Secondary Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy